![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Departments of Medicine (R.R.R., J.A.A., C.Y., S.G.), Biochemistry (S.G.), and Pharmacology (S.G.), Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia
The functional significance of disruption of p21WAF1/CIP1 induction by flavopiridol (FP) in human leukemia cells (Jurkat) exposed to the histone deacetylase (HDAC) inhibitor sodium butyrate (SB) was investigated. Coexposure of leukemic cells to FP blocked SB-mediated induction of p21WAF1/CIP1 and resulted in a marked increase in mitochondrial injury, activation of procaspases-3 and -8, Bid cleavage, and PARP degradation. Enforced expression of p21WAF1/CIP1 (i.e., in Jurkat cells inducibly expressing p21WAF1/CIP1 under the control of a doxycycline-responsive promoter) partially but significantly reduced cytochrome c and apoptosis-inducing factor release, loss of mitochondrial membrane potential, caspase-3 and -8 activation, Bid cleavage, poly(ADP-ribose)polymerase (PARP) degradation, and apoptosis in response to SB/FP. Furthermore, increasing expression of p21WAF1/CIP1 (i.e., by culturing cells in the presence of higher concentrations of doxycycline) rendered cells more resistant to SB/FP-mediated lethality. Enforced expression of p21WAF1/CIP1 did not modify SB/FP-mediated JNK activation or generation of reactive oxygen species. Consistent with these results, Jurkat cells stably expressing a p21WAF1/CIP1 nuclear localization mutant (p21
NLS) were also resistant to SB/FP-mediated mitochondrial injury, activation of procaspases-3 and -8, PARP cleavage, and apoptosis. Finally, enforced expression of full-length or ectopic expression of NLS p21WAF1/CIP1 increased the amount of p21WAF1/CIP1 coimmunoprecipitating with procaspase-3. Together, these findings suggest that interruption of HDAC-mediated p21WAF1/CIP1 induction by FP plays a significant functional role in potentiating apoptosis, possibly by preventing the formation of a procaspase-3/p21WAF1/CIP1 complex.
Address correspondence to: Dr. Steven Grant, Medical College of Virginia, Virginia Commonwealth University, MCV Station Box 230, Richmond, VA 23298. E-mail: stgrant{at}hsc.vcu.edu
This article has been cited by other articles:
|
|
 |
|
  M. E. Smith, V. Cimica, S. Chinni, K. Challagulla, S. Mani, and G. V. Kalpana Rhabdoid Tumor Growth is Inhibited by Flavopiridol Clin. Cancer Res., January 15, 2008; 14(2): 523 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Brest, M. Gustafsson, A.-K. Mossberg, L. Gustafsson, C. Duringer, A. Hamiche, and C. Svanborg Histone Deacetylase Inhibitors Promote the Tumoricidal Effect of HAMLET Cancer Res., December 1, 2007; 67(23): 11327 - 11334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Mitchell, M. A. Park, G. Zhang, A. Yacoub, D. T. Curiel, P. B. Fisher, J. D. Roberts, S. Grant, and P. Dent Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells Mol. Cancer Ther., December 1, 2007; 6(12): 3101 - 3112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. F. Peterson, M. Yan, and D.-E. Zhang The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO Blood, May 15, 2007; 109(10): 4392 - 4398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Rosato, J. A. Almenara, S. S. Kolla, S. C. Maggio, S. Coe, M. S. Gimenez, P. Dent, and S. Grant Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions Mol. Cancer Ther., February 1, 2007; 6(2): 692 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Duan, J. Friedman, L. Nottingham, Z. Chen, G. Ara, and C. Van Waes Nuclear factor-{kappa}B p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101 Mol. Cancer Ther., January 1, 2007; 6(1): 37 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Geng, K. C. Cuneo, A. Fu, T. Tu, P. W. Atadja, and D. E. Hallahan Histone Deacetylase (HDAC) Inhibitor LBH589 Increases Duration of {gamma}-H2AX Foci and Confines HDAC4 to the Cytoplasm in Irradiated Non-Small Cell Lung Cancer Cancer Res., December 1, 2006; 66(23): 11298 - 11304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Fiskus, M. Pranpat, M. Balasis, P. Bali, V. Estrella, S. Kumaraswamy, R. Rao, K. Rocha, B. Herger, F. Lee, et al. Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate-Sensitive or Imatinib Mesylate-Resistant Chronic Myelogenous Leukemia Cells. Clin. Cancer Res., October 1, 2006; 12(19): 5869 - 5878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. I. Shapiro Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment J. Clin. Oncol., April 10, 2006; 24(11): 1770 - 1783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Rosato, J. A. Almenara, S. C. Maggio, P. Atadja, R. Craig, J. Vrana, P. Dent, and S. Grant Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells Mol. Cancer Ther., November 1, 2005; 4(11): 1772 - 1785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Acharya, A. Sparreboom, J. Venitz, and W. D. Figg Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review Mol. Pharmacol., October 1, 2005; 68(4): 917 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Gao, Y. Dai, M. Rahmani, P. Dent, and S. Grant Contribution of Disruption of the Nuclear Factor-{kappa}B Pathway to Induction of Apoptosis in Human Leukemia Cells by Histone Deacetylase Inhibitors and Flavopiridol Mol. Pharmacol., October 1, 2004; 66(4): 956 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Grant and P. Dent Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: What's in a name? Mol. Cancer Ther., July 1, 2004; 3(7): 873 - 875. [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
